The groundbreaking treatment known as GD (Gamma Delta) T-cell therapy has begun Phase 2 clinical trials. The purpose of this trial, which is being carried out in partnership with CytoMed, Singapore, is to give patients with cancers that are hard to treat such as brain, breast, lung, cervical, colon, renal, liver, lymph node, and several others, hope.